Compare Novo Nordisk A/S (NVO) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Petróleo Brasileiro SA — how do they compare? Novo Nordisk A/S trades at $46.1 (market cap $207.85B), while Petróleo Brasileiro SA trades at $17.9 (market cap $112.19B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Petróleo Brasileiro SA pays the higher dividend (9.42%). Which is the better fit depends on your goals.
| NVO | PBR | |
|---|---|---|
Market Cap | $207.85B | $112.19B |
Sector | Health | Technology |
52-Week High | $63.98 | $22.03 |
52-Week Low | $35.29 | $11.54 |
Enterprise Value | $222.55B | $172.61B |
Dividend Yield | 3.81% | 9.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Petrobras (PBR) trades at $17.93, down 2.18% today, showing strong fundamentals with a P/E of 4.53 and robust profitability margins. Recent Q2 2026 earnings beat expectations with EPS of $1.60 versus $1.40 expected, driven by record production and higher oil prices. Technical indicators signal bearish momentum, with RSI at oversold levels near 20.31, while analyst consensus remains positive with 50% buy ratings.
The outlook remains favorable due to cheap valuations and production growth, but risks include regulatory uncertainty and volatile oil prices. Investment opportunity lies in sustained dividend payments and operational efficiency, though geopolitical and macroeconomic factors could pressure near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
